RxDoctor Payments Data

Kristen Scarpato, MD

Urology · Nashville, TNNPI 1164659801

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $15,250 of the $23,973 with a category attached, or 63.6%. Photocure Inc accounts for 63.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $13,597 and has fallen 94.3% since, to $780 in 2025.

$23,973in general payments, 2019–2025

Across 57 payments — averaging $420.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Photocure Inc$15K
  • Urogen Pharma, Inc.$5K
  • KARL Storz Endoscopy-america$2K
  • Ferring Pharmaceuticals Inc.$488
  • Johnson & Johnson$402
  • Intuitive Surgical$309
  • plus $829 from 5 others
$40,000in research payments, 2019–2025

Across 3 payments — averaging $13,333 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$40K

What the payments were for

  • Consulting fees$5,25022%
  • Speaking & faculty fees$15,25064%
  • Food & beverage$3,45014%
  • Education$230%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,973 in reported general payments places this provider in the 85th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$40,027
Medicare patients
205
Services billed
441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide12$136,106
OrgovyxRelugolix48$120,828

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$199$136,10612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 276 urology providers in Tennessee.

Other urology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →